Medicenna Therapeutics stock reports a November data milestone
Published on 09/24/2026 at 14:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medicenna Therapeutics stock stood at CAD 0.41 on the TSX on September 23, 2026, down 1.22 percent from the prior session. On September 24, the company announced that new bizaxofusp results in recurrent glioblastoma had been selected for an oral presentation.
November brings a data milestone
According to Digital Journal on September 24, 2026, the presentation will examine survival outcomes with bizaxofusp, formerly known as MDNA55, in unresectable IDH-wildtype recurrent glioblastoma. The session is scheduled for the Society for Neuro-Oncology annual meeting in Philadelphia from November 12 to November 15, 2026.
The presentation gives Medicenna a defined clinical checkpoint for its lead program. The company is developing engineered cytokine therapies called Superkines for cancer and autoimmune disease, with bizaxofusp positioned as an IL-4 based treatment candidate, according to Digital Journal.
Price remains below the yearly high
The market value was CAD 31,435,007 on September 23, 2026, while daily volume was 1,757 shares against an average volume of 54,396. That contrast puts the session move into a low-volume setting rather than a broad trading surge.
Medicenna Therapeutics stock was 79.2 percent below its 52-week high of CAD 1.97 and 20.6 percent above its 52-week low of CAD 0.34 on the same date. The wide range leaves the November presentation as a concrete event for investors tracking whether clinical evidence can change the valuation narrative.
TSX listing sets the reference
The TSX quote is the relevant reference for the Canadian issuer, with the share price expressed in CAD. Medicenna's pipeline and its upcoming oral presentation remain clinical-stage developments, so the November event is primarily an evidence checkpoint rather than a commercial revenue milestone.
At CAD 0.41 on September 23, 2026, the stock carried a market capitalization of CAD 31,435,007 and remained below the midpoint of its 52-week range of CAD 0.34 to CAD 1.97.
Medicenna Therapeutics snapshot
- Company: Medicenna Therapeutics Corp.
- Ticker: MDNA
- Trading venue: TSX
- Closing price (September 23, 2026): CAD 0.41
- Daily change: -1.22 percent
- Market capitalization: CAD 31,435,007 (as of September 23, 2026)
- 52-week range: CAD 0.34-1.97 (as of September 23, 2026)
- Sector / Industry: Healthcare / Biotechnology
